All In Biotech

Drug Trial Radar · NCT04956289

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls

Last checked: Nov 20, 2026Latest source record: Aug 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Jul 1, 2021

Primary completion

Jun 20, 2023

Study completion Jul 13, 2023

Sponsor

Lead sponsor
NS Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Nippon Shinyaku Co., Ltd.
First posted
Jul 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD patients over the age of 8 years.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • ViltolarsenDrug

    Received during weekly intravenous infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse EventsTime frame: baseline to up to 48 weeks of treatment
  2. Number of Participants With Treatment Emergent Adverse Events by Maximum SeverityTime frame: baseline to up to 48 weeks of treatment
  3. Number of Participants With Treatment Emergent Adverse Events by Highest Intervention Level Regarding Investigational ProductTime frame: baseline to up to 48 weeks of treatment
  4. Number of Participants With Treatment Emergent Adverse Events by Worst OutcomeTime frame: baseline to up to 48 weeks of treatment
  5. Number of Participants With Investigational Product-related Treatment Emergent Adverse EventsTime frame: baseline to up to 48 weeks of treatment
  6. Number of Participants With Investigational Product-related Treatment Emergent Adverse Events by Maximum SeverityTime frame: baseline to up to 48 weeks of treatment
  7. Number of Participants With Investigational Product-related Treatment Emergent Adverse Events by Highest Intervention Level Regarding Investigational ProductTime frame: baseline to up to 48 weeks of treatment
  8. Number of Participants With Investigational Product-related Treatment Emergent Adverse Events by Worst OutcomeTime frame: baseline to up to 48 weeks of treatment
  9. Number of Participants With Adverse Event of Special InterestTime frame: baseline to up to 48 weeks of treatment

Locations

8 sites in 6 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Richmond at VCU

    Richmond, Virginia

  • The Third Medical Center of PLA General Hospital

    Beijing, China

  • Hunan Children's Hospital

    Changsha, China

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Roma, Italy

  • Russian National Research Medical University

    Moscow, Russia

  • Saint Petersburg State Paediatric Medical University

    Saint Petersburg, Russia

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.